Von Willebrand disease is the most common hereditary bleeding disorder (1 in every 10.000 people), which is caused by abnormalities in the plasma protein Von Willebrand factor. In Von Willebrand disease, small injuries can already lead to severe bleeding due to the disrupted blood clotting. Current treatment focuses on increasing the concentration of the Von Willebrand factor in the blood, but this has proven to be insufficiently effective in many patients and a need for more personalized treatment that addresses the causes of the disease has arisen. In a research project funded by NWO, researchers involved from LUMC, Erasmus MC, and Amsterdam UMC will join forces and develop innovative, personalized treatment strategies for patients with Von Willebrand disease.
Three PhD students will be appointed to this project (one in each participating center) to develop novel gene therapy strategies based on RNA interference and CRISPR gene correction. The project will use patient-derived cellular disease models, animal models, and vectors optimally targeted to the vessel wall.Work environment
The Department of Hematology has pioneered innovative methods to understand the mechanisms of hematological disease on a molecular and cellular level. The Erasmus MC is the largest treatment center for bleeding disorders in the Netherlands. Together with the department of Pediatric Hematology our department operates within the Academic Center of Excellence Hemostasis and Thrombosis, where our clinical and basic research revolves around finding out why patients bleed or suffer from thrombosis and how to improve their treatment.
Our research is very well supported by genetic and clinical research of patients with bleeding disorders, including the largest cohort study of patients with Von Willebrand disease in the world, the Willebrand in the Netherlands (WiN) study. Combination of our patient cohort studies with cutting-edge molecular and cellular technologies on patient cells provides the unprecedented opportunity to perform innovative research on the biological mechanisms of bleeding disorders and to make discoveries that impact the routine practice of patient care.Qualifications and skills
Before you apply please check our conditions for employment.Terms of employment
You will receive a temporary position for 4 years. The gross monthly salary is € 2.495,- in the 1st year and increases to € 3.196,- in the 4th year (scale OIO). The terms of employment are according to the Collective Bargaining Agreement for Dutch University Medical Centers (CAO UMC).Information and application
For more information about this position, please contact Dr. Ruben Bierings, group leader Hematology, phone number: +31(0)10 704 37 72 or e-mail: firstname.lastname@example.org or Prof. dr. Frank Leebeek, Head of Department Hematology, phone +31(0)10 703 37 44 or email: email@example.com.
For queries regarding your application, please contact Jerry Chandansingh, Recruiter, by phone number: +31 (0)6 500 310 06.
If you are excited by the thought of this position and would like to apply, please do so by using the application form on our website. Two similar positions within this research project are open at LUMC and Amsterdam UMC. Giving a presentation is part of the procedure and two references will be requested for this vacancy. For now we only require your CV and motivational letter.
No agencies please.